Table 3.
Unadjusted incidence rates of venous thromboembolic events after cancer diagnosis among older STS patients
| DVTa | PEa | OTEa | ||||
|---|---|---|---|---|---|---|
| N/P-Yb | Rate/1,000c (95% CI) | N/P-Yb | Rate/1,000c (95% CI) | N/P-Yb | Rate/1,000c (95% CI) | |
| By major STS subtype | ||||||
| Angiosarcoma (n = 184) | 14/147 | 95.4 (52.1, 160.0) | <11 | 26.5 (7.2, 68.0) | <11 | 39.8 (14.6, 86.6) |
| Fibrosarcoma (n = 64) | <11 | 72.1 (19.6, 184.5) | 0 | 0 | <11 | 17.6 (0.4, 97.8) |
| GIST (n = 845) | 94/683 | 137.6 (111.2, 168.4) | 33/721 | 45.7 (31.5, 64.2) | 23/730 | 31.5 (20.0, 47.3) |
| Leiomyosarcoma (n = 264) | 19/210 | 90.6 (54.5, 141.4) | <11 | 28.0 (10.3, 60.8) | <11 | 32.6 (13.1, 67.1) |
| Liposarcoma (n = 224) | 13/118 | 110.1 (58.6, 188.2) | <11 | 24.5 (5.1, 71.7) | <11 | 24.5 (5.0, 71.5) |
| MFH (n = 184) | 20/178 | 112.2 (68.5, 173.3) | <11 | 21.9 (6.0, 55.9) | <11 | 27.3 (8.9, 63.6) |
| Nerve sheath tumor (n = 118) | 15/93 | 160.8 (90.0, 265.3) | <11 | 40.7 (11.1, 104.2) | <11 | 49.8 (16.2, 116.3) |
| Sarcoma, NOS (n = 1,422) | 166/812 | 204.4 (174.5, 237.9) | 41/862 | 47.5 (34.1, 64.5) | 41/858 | 47.8 (34.3, 64.8) |
| By history of VTEe | ||||||
| Yes | 61/51 | 1199.2 (917.3–1540.5) | 11/14 | 785.5 (392.3–1406.0) | 30/50 | 599.2 (404.3–855.4) |
| No | 306/2,417 | 126.6 (112.8–141.6) | 94/2,575 | 27.6 (24.3–31.1) | 76/2,540 | 29.9 (23.6–37.5) |
| Rate ratio (yes vs. no)d | – | 9.5 (7.2–12.5) | – | 21.5 (11.5–40.2) | – | 20.0 (13.1–30.6) |
| By history of CVD eventf | ||||||
| Yes | 120/579 | 207.3 (171.9–247.9) | 29/623 | 46.6 (31.2–66.9) | 39/619 | 63.1 (44.8–86.2) |
| No | 247/1,889 | 130.8 (115.0–148.1) | 76/1,966 | 38.7 (30.5–48.4) | 67/1,971 | 34.0 (26.3–43.2) |
| Rate ratio (yes vs. no)d | – | 1.6 (1.3–2.0) | 1.2 (0.8–1.8) | 1.9 (1.3–2.8) | ||
| By disease stage | ||||||
| Localized | 133/1,236 | 107.6 (90.1–127.5) | 38/1,290 | 29.5 (20.9–40.4) | 34/1,295 | 26.3 (18.2–36.7) |
| Regional | 93/586 | 158.7 (128.1–194.4) | 26/614 | 42.3 (27.7–62.1) | 34/610 | 55.7 (38.6–77.9) |
| Distant | 86/380 | 238.9 (191.1–295.0) | 25/385 | 65.0 (42.1–95.9) | 19/387 | 49.1 (29.6–76.7) |
| Rate ratio (regional and distant. vs. local)d | – | 1.5 (1.1–1.9) | – | 1.4 (0.9–2.4) | – | 2.1 (1.3–3.4) |
| By chemotherapy | ||||||
| Yes | 74/324 | 227.9 (178.9–286.1) | 20/348 | 57.5 (35.1–88.7) | 19/346 | 54.9 (33.0–85.7) |
| No | 293/2,413 | 136.7 (121.5–153.3) | 85/2,241 | 37.9 (30.3–46.9) | 87/2,244 | 38.8 (31.1–47.8) |
| Rate ratio (yes vs. no)d | – | 1.7 (1.3–2.2) | – | 1.5 (0.9–2.5) | 1.4 (0.9–2.3) | |
| By surgery of primary tumor | ||||||
| Yes | 247/1,976 | 125.0 (109.9–141.6) | 72/2,065 | 34.9 (27.3–43.9) | 76/2,064 | 36.8 (29.0–46.1) |
| No | 115/467 | 246.4 (203.5–295.8) | 32/498 | 64.2 (43.9–90.7) | 29/501 | 57.9 (38.8–83.1) |
| Rate ratio (yes vs. no)d | – | 0.5 (0.4–0.6) | – | 0.5 (0.4–0.8) | – | 0.6 (0.4–1.0) |
| By Primary site | ||||||
| Connective/subcutaneous | 136/830 | 163.9 (137.5–193.8) | 33/877 | 37.6 (25.9–52.8) | 37/875 | 42.3 (29.8–58.3) |
| Digestive system | 120/832 | 144.2 (119.5–172.4) | 38/879 | 43.2 (30.6–59.4) | 29/885 | 32.8 (22.0–47.1) |
| Other/unknowng | 111/805 | 137.8 (113.3–165.9) | 34/833 | 40.8 (28.3–57.0) | 40/830 | 48.2 (34.4–65.7) |
Per SEER-Medicare data use agreement, cell sizes <11 cannot be displayed, nor can estimates that could be used to derive the undisplayed numbers <11. Rate ratios are highlighted in italics.
a DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
b N number of VTE events, P-Y person-years.
cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (≥65 years) of STS patients. Only first VTE counted in rate estimates.
dRate ratios are unadjusted.
eHistory of VTE of interest in the 12 months before STS diagnosis.
fHistory of CVD is defined as a history of any of the following events in the 12 months before STS diagnosis: myocardial infarction, ischemic stroke, onset congestive heart failure, angina, or TIA.
gOther/unknown category includes primary sites of the breast, female genital system, other non-epithelial, respiratory system, urinary system, other sites and unknown sites.